
    
      This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory
      syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to
      24 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and
      antiviral activity of a 5 day treatment with EDP-938.
    
  